 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 3 | 1/1 | 返回列表 |
| 查看: 659 | 回復: 2 | |||
狼行拂曉榮譽版主 (著名寫手)
~~~~
|
[交流]
Novo Nordisk to Initiate Phase 3a Development of Oral Semaglutide 已有2人參與
|
|
Novo Nordisk to Initiate Phase 3a Development of Oral Semaglutide, a Once-Daily Oral GLP-1 Analogue Bagsværd, Denmark, 26 August 2015 - Novo Nordisk today announced the decision to initiate a phase 3a programme with oral semaglutide; a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows the encouraging results of the proof-of-concept phase 2 trial announced on 20 February 2015 and the subsequent consultations with regulatory authorities. Novo Nordisk intends to initiate a global phase 3a programme, named PIONEER, comprising seven trials with approximately 8,000 people with type 2 diabetes. The PIONEER programme will include six safety and efficacy trials and one trial for evaluating the cardio-vascular safety of oral semaglutide. The first trial in the programme is planned for initiation in first quarter of 2016 and will investigate the efficacy and safety of once-daily oral semaglutide doses of 3 mg, 7 mg and 14 mg, compared to once-daily oral anti-diabetic sitagliptin dose of 100 mg. The remaining six trials of the PIONEER programme are all expected to be initiated during 2016. In order to meet capacity requirements for current and future diabetes care products, including oral semaglutide, Novo Nordisk expects to invest an estimated 2 billion US dollars over the coming five years in two new production facilities; a new production facility for a range of active pharmaceutical ingredients in Clayton, North Carolina, US and a new drug-product facility in Måløv, Denmark. The final design and cost of the new production facilities will be presented for approval by the company's board of directors in 2016. "Delivering protein-based medicine like semaglutide in the form of a tablet and producing it on a large scale is a major challenge, and with the announcement today we have reached a significant milestone towards achieving that goal", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We are excited about the opportunities oral semaglutide represents as a new oral anti-diabetic agent to further improve type 2 diabetes treatment". About Semaglutide Semaglutide (NN9924) is a new glucagon-like peptide-1 (GLP-1) analogue that can help people with type 2 diabetes achieve substantial lowering of blood glucose with a low risk of hypoglycaemia. In addition, semaglutide induces weight loss by decreasing appetite and food intake. The oral formulation of semaglutide is provided in a tablet formulation with SNAC, an absorption-enhancing excipient included in the Eligen® Carrier Concept. The Eligen® technology is licenced from Emisphere Technologies, Inc. Source: Novo Nordisk Posted: August 2015 |
回復此樓» 猜你喜歡
26考博申請 學or專
已經有15人回復
-
中國藥科大學2026入學博士，藥物合成和設計經驗，放射化學及放射醫(yī)學研究
已經有25人回復
-
藥物學論文潤色/翻譯怎么收費?
已經有259人回復
-
使用MolAICal進行多肽虛擬篩選教程-同樣適用于蛋白質和核酸的虛擬篩選
已經有1人回復
-
使用MolAICal計算藥物化學過濾器MCFs及MCE-18描述符
已經有0人回復
-
使用MolAICal發(fā)現(xiàn)蛋白受體潛在的活性口袋及位點
已經有0人回復
-
華理藥學學碩求調劑，總分324
已經有0人回復
-
澳門理工大學人工智能藥物發(fā)現(xiàn)中心招收2026級博士研究生（申請-考核制）
已經有9人回復
voyager88
金蟲 (著名寫手)
- DRDEPI: 11
- 應助: 584 (博士)
- 金幣: 2387
- 散金: 4182
- 紅花: 338
- 帖子: 1994
- 在線: 551.7小時
- 蟲號: 1259270
- 注冊: 2011-04-08
- 專業(yè): 藥劑學
2樓2015-09-01 13:52:11
GeniusCai
銅蟲 (初入文壇)
- 應助: 0 (幼兒園)
- 金幣: 716.1
- 帖子: 42
- 在線: 16.2小時
- 蟲號: 2362462
- 注冊: 2013-03-20
- 性別: GG
- 專業(yè): 藥物化學
3樓2015-09-10 22:43:50
相關版塊跳轉
我要訂閱樓主 狼行拂曉 的主題更新
| 3 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 材料專業(yè)求調劑 +5 | hanamiko 2026-03-18 | 5/250 |
|
|---|---|---|---|---|
|
|
[考研] 311求調劑 +11 | 冬十三 2026-03-15 | 12/600 |
|
|
|
[考研] 0854可跨調劑，一作一項核心論文五項專利，省、國級證書40+數一英一287 +8 | 小李0854 2026-03-16 | 8/400 |
|
|
[考研] 0703化學336分求調劑 +6 | zbzihdhd 2026-03-15 | 7/350 |
|
|
|
[基金申請] 被我言中：新模板不強調格式了，假專家開始管格式了 +4 | beefly 2026-03-14 | 4/200 |
|
|
|
[考研] 26考研求調劑 +6 | 丶宏Sir 2026-03-13 | 6/300 |
|
|
|
[考研] 有沒有道鐵/土木的想調劑南林，給自己招師弟中～ +3 | TqlXswl 2026-03-16 | 7/350 |
|
|
|
[考研] 283求調劑 +3 | 聽風就是雨； 2026-03-16 | 3/150 |
|
|
|
[考研] 274求調劑 +5 | 時間點 2026-03-13 | 5/250 |
|
|
|
[考研] 070300化學學碩求調劑 +6 | 太想進步了0608 2026-03-16 | 6/300 |
|
|
|
[考研] 0856求調劑 +3 | 劉夢微 2026-03-15 | 3/150 |
|
|
|
[考研] 070305求調劑 +3 | mlpqaz03 2026-03-14 | 4/200 |
|
|
|
[考研] 289求調劑 +4 | 這么名字咋樣 2026-03-14 | 6/300 |
|
|
|
[考研] 中科大材料專碩319求調劑 +3 | 孟鑫材料 2026-03-13 | 3/150 |
|
|
|
[考研] 265求調劑 +4 | 威化餅07 2026-03-12 | 4/200 |
|
|
|
[基金申請] 現(xiàn)在如何回避去年的某一個專家，不知道名字 +3 | zk200107 2026-03-12 | 6/300 |
|
|
|
[考研] 266求調劑 +4 | 學員97LZgn 2026-03-13 | 4/200 |
|
|
|
[考研] 招收0805（材料）調劑 +3 | 18595523086 2026-03-13 | 3/150 |
|
|
|
[考研] 材料與化工求調劑一志愿 985 總分 295 +8 | dream…… 2026-03-12 | 8/400 |
|
|
|
[考研] 0703化學求調劑 +7 | 綠豆芹菜湯 2026-03-12 | 7/350 |
|